

1 **Article title: “Incidence and Outcomes of Pulmonary embolism among hospitalized COVID-19**  
2 **patients”**

3

4 **Short running title: Pulmonary embolism and COVID-19**

5 **Authors’ names:**

6 Omaima Ibrahim Badr, M.D,<sup>1,2</sup> Hassan Alwafi, M.D,<sup>3</sup> Wael Aly Elrefaey, MD,<sup>2</sup> Abdallah Y Naser,  
7 PhD,<sup>4</sup> Mohammed Shabrawishi, M.D,<sup>2,5</sup>

8

9 **Authors affiliations:**

10 <sup>1</sup>Department of Chest Medicine, Mansoura University, Faculty of medicine, Egypt.

11 <sup>2</sup>Department of Pulmonary Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia,

12 <sup>3</sup>Department of Clinical Pharmacology and Toxicology, Faculty of Medicine, Umm Al Qura  
13 University, Mecca, Saudi Arabia.

14 <sup>4</sup>Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra  
15 University, Amman, Jordan.

16 <sup>5</sup>Department of Internal Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.

17

18 **Corresponding author**

19 Dr.Hassan Alwafi

20 Department of Clinical Pharmacology and Toxicology

21 Umm Alqura University, Faculty of Medicine

22 Mecca, Saudi Arabia

23 Post Code 24381

24 T +966555544319

25 Email: [hhwafi@uqu.edu.sa](mailto:hhwafi@uqu.edu.sa)

26

27

28 Number of words in abstract: 254

29 Number of words in main body text: 2531

30 Number of tables in main body text: 4

31 Number of references in main body text: 26

32

33

34 **Abstract**

35 **Background:** Patients with COVID-19 may be at high risk for thrombotic complications due to excess  
36 inflammatory response and stasis of blood flow. This study aims to assess the incidence of pulmonary  
37 embolism among hospitalized patients with COVID-19, risk factors and the impact on survival.

38 **Method:** A retrospective case-control study was conducted at Al-Noor Specialist Hospital in, Saudi  
39 Arabia between March 15, 2020, and June 15, 2020. Patients with confirmed COVID-19 diagnosis by  
40 a real-time polymerase chain reaction (PCR) and confirmed diagnosis of pulmonary embolism by  
41 Computed Tomography pulmonary angiogram (CTPA) formed the case group. Patients with  
42 confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) and without  
43 confirmed diagnose of pulmonary embolism formed the control group. Logistic regression analysis  
44 was used to identify predictors of pulmonary embolism and its survival.

45 **Results:** A total of 159 patients participated were included in the study, of which 51 were the cases  
46 (patients with pulmonary embolism) and 108 patients formed the control group (patients without  
47 pulmonary embolism). The incidence of PE among hospitalized was around 32%. Smoking history, low  
48 level of oxygen saturation and higher D-dimer values were important risk factors that were associated  
49 with a higher risk of developing PE ( $p < 0.05$ ). Higher respiratory rate was associated with higher odds  
50 of death, and decrease the possibility of survival among hospitalised patients with PE.

51 **Conclusion:** Pulmonary embolism is common among hospitalized patients with COVID-19. Preventive  
52 measures should be considered for hospitalized patients with smoking history, low level of oxygen  
53 saturation, high D-dimer values, and high respiratory rate.

54 **Keywords:** COVID-19; Hospitalized; Pulmonary embolism; Survival

55

56

57

58

59

60

61

62

## 63 **Introduction**

64 The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in  
65 Wuhan city, China at the end of 2019 and since then it has spread in more than 190 countries across  
66 the world. The total number of confirmed cases as of August 2020 was  $\approx$ 20 million, with  $\approx$  700,000  
67 confirmed deaths (1). The severity of the disease can range from being asymptomatic, mild or  
68 moderate to severe, with multi-organ failure and death (2, 3). Acute respiratory distress syndrome,  
69 which is one of the major complications of coronavirus disease of 2019 (COVID-19), is associated  
70 with a high mortality rate and is considered the main cause of death (4, 5). Venous and arterial  
71 thrombosis is considered one of the most severe consequences of the disease and has poor prognostic  
72 outcomes (6, 7). Patients with COVID-19 may be at a high risk of thrombotic complications due to  
73 excess inflammatory response, platelet activation, endothelial dysfunction, and stasis of blood flow (8,  
74 9). At present, it has been suggested that patients with COVID-19 infection have an increased risk of  
75 thrombosis (10). In addition, recent data has suggested that increased levels of the D-dimer test can be  
76 a predictor of adverse outcomes such as underlying coagulopathy and thrombotic risk in patients with  
77 COVID-19 (11, 12). However, the published data are very limited, with no previous studies on the  
78 incidence and risk factors of PE in patients with COVID-19 in the Middle East. Therefore, this study  
79 aims to assess the incidence of pulmonary embolism among hospitalized patients with COVID-19,  
80 risk factors, and the impact on survival.

## 81 **METHODS**

### 82 **Study Design and participants**

83 A retrospective case-control study was conducted at Al-Noor Specialist Hospital in Mecca, Saudi  
84 Arabia. The description of the study settings and the hospital has been described previously (1). All  
85 patients had a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR). The  
86 PCR samples were obtained through a nasopharyngeal swap. The patients underwent a Computed  
87 Tomography pulmonary angiogram (CTPA) for the diagnosis of pulmonary embolism (PE). All  
88 patients were admitted between March 15, 2020, and June 15, 2020, and they were followed up for a  
89 time to assess the clinical outcome, and the final date of follow-up was August 15, 2020. Patients  
90 younger than 15 years old, and patients who were not eligible for CTPA pulmonary angiography,  
91 were excluded from the study.

### 92 **Data Collection and study variables**

93 Data were collected from medical files and electronic records using a unique medical record number  
94 (MRN) for each patient. Data included the patient's demographics, clinical symptoms (fever, cough,  
95 SOB, nausea, vomiting, diarrhoea, headache, body aches, loss of smell and loss of taste),  
96 comorbidities and chest radiograph. These data were collected on admission to the hospital. Clinical  
97 signs, including heart rate, respiratory rate and SO<sub>2</sub>% on room air, were collected at the time of  
98 CTPA. Data regarding risk assessments for thromboembolism including age, smoking, obesity  
99 (defined as BMI  $\geq$  30), D-dimer level, the severity of the disease (critical (in ICU) and non-critical  
100 (outside ICU)), the time between the admission and the CTPA, the presence of comorbidities, the risk  
101 of disseminated intravascular coagulation (DIC), including CBC (WBC, platelets and haemoglobin  
102 level), and the coagulation parameters (PT, PTT and INR) were collected in the same day or within 24  
103 hours of the Computed Tomography pulmonary angiogram (CTPA). The radiological examinations  
104 including the CTPA were reviewed by a senior certified chest radiologist that classified the pulmonary  
105 embolism to the main trunk, lobar, segmental and subsegmental; RV strain by CT was defined as a  
106 right ventricle to left ventricle size ratio of  $\geq$  0.9. In addition, pulmonary systolic pressure, right  
107 ventricular (RV) dysfunction (diagnosed by qualitative and quantitative RV dilation or RV systolic  
108 dysfunction), left ventricular (LV) dysfunction (defined as decreased left ventricular systolic function  
109 with decreased LV ejection fraction, regional wall motion abnormalities or both), and visualization of  
110 thrombus in the right heart or the pulmonary artery were diagnosed through trans-thoracic  
111 echocardiography, which was reviewed by an experienced, board-certified echocardiography  
112 attending physician.

### 113 **Case definition**

114 Patients with a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) and  
115 without a confirmed diagnosis of pulmonary embolism formed the control group.

### 116 **Control definition**

117 Patients with a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) and  
118 without a confirmed diagnosis of pulmonary embolism formed the control group.

### 119 **Outcomes**

120 The outcome predictors of those patients were admission to an intensive care unit, intubation and  
121 connection to mechanical ventilation, thrombolytic therapy or catheter-directed thrombolysis, bleeding  
122 (minor or major bleeding) as a complication of PE therapy, a prolonged hospital stay ( $\geq$  2 weeks), and  
123 mortality.

### 124 **Statistical Analysis**

125 Descriptive statistics were used to describe patients' demographic characteristics, radiological  
126 findings, clinical signs and symptoms, and comorbidities. Continuous data were reported as mean  $\pm$   
127 SD for normally distributed data and as median (interquartile range (IQR)) for not normally  
128 distributed data, and categorical data were reported as percentages (frequencies). Independent sample  
129 t-test/ANOVA was used to compare the mean value for normally distributed continuous variables and  
130 The Mann-Whitney U test/Kruskal-Wallis test was used to compare the median value for not normally  
131 distributed ones. A Chi-squared test/Fisher test was used as appropriate to compare proportions for  
132 categorical variables. Logistic regression analysis was used to identify predictors of pulmonary  
133 embolism and its survival. A confidence interval of 95% ( $p < 0.05$ ) was applied to represent the  
134 statistical significance of the results, and the level of significance was assigned as 5%. SPSS  
135 (Statistical Package for the Social Sciences) version 25.0 software (SPSS Inc.) was used to perform all  
136 statistical analysis.

137 **Ethical approval:** This study was approved by the institutional ethics board at the Ministry of Health  
138 in Saudi Arabia (No H-02-K-076-0920-386).

#### 139 **Patient and public involvement**

140 It was not appropriate or possible to involve patients or the public in the design, or conduct, or  
141 reporting, or dissemination plans of our research.

## 142 **Results**

### 143 **Patient's baseline characteristics**

144 A total of 159 patients participated in the study, of which 51 were the cases (patients with pulmonary  
145 embolism) and 108 patients formed the control group (patients without pulmonary embolism). The  
146 incidence of PE among hospitalized patients was around 32%. The case and control group showed  
147 comparable baseline characteristics; there was no statistically significant difference between the two  
148 groups in term of the gender distribution, duration of stay at the hospital, disease history, and most of  
149 the reported signs and symptoms ( $p > 0.05$ ). For further details on the baseline characteristics, refer to  
150 **Table 1** below.

### 151 **Vital signs and blood test findings**

152 The case and control groups were comparable in terms of their vital sign measurements (respiratory  
153 rate, heart rate, oxygen saturation) and various blood test measurements (haematocrit, HGB, WBC,  
154 INR, and PTT). However, PT and D-dimer measures were significantly different between the two  
155 groups, where the mean PT value was higher in the control group compared to the case group, and the

156 median D-dimer value was higher among the case group compared to the control group. For further  
157 details on vital signs and blood test findings, refer to **Table 2**.

### 158 **Patient's radiological findings**

159 The majority of pulmonary emboli were located in the segmental branch. There was no statistically  
160 significant difference between the case and the control groups in terms of the CT parenchymal  
161 findings ( $p > 0.05$ ). RT ventricular dysfunction was more common among the case group compared to  
162 the control group, whereas the distribution of LT ventricular dysfunction and systolic pulmonary  
163 embolism between the two groups was the same (**Table 3**).

### 164 **Risk factors of pulmonary embolism and its survival.**

165 Using unadjusted logistic regression, we identified that age, smoking history, a higher respiratory rate,  
166 and a higher D-dimer value were associated with a higher risk of developing PE ( $p < 0.05$ ). A higher  
167 respiratory rate, higher WBC, higher INR value, longer duration between admission and spiral, longer  
168 duration of stay at the hospital, requiring ICU admission, duration of stay at the ICU, and requiring  
169 intubation were associated with higher odds of death, and a decrease in the possibility of survival  
170 among hospitalized patients with PE ( $p < 0.05$ ). On the other hand, a higher HGB value was  
171 associated with higher odds of survival ( $p < 0.05$ ).

172 Adjusting for relevant confounding variables such as age, gender, BMI, renal failure, malignancy,  
173 haematological diseases, duration between admission and spiral, duration in the ICU, and intubation,  
174 we identified that smoking history, a low level of oxygen saturation, and higher D-dimer values were  
175 important risk factors that were associated with a higher risk of developing PE ( $p < 0.05$ ). A higher  
176 respiratory rate was associated with higher odds of death, and a decrease in the possibility of survival  
177 among hospitalized patients with PE. For further details on the findings of the logistic regression  
178 analysis, refer to **Table 4**.

### 179 **Discussion**

180 To the best of our knowledge, this is the first study that investigated the incidence and risk factors of  
181 pulmonary embolism among hospitalized patients with COVID-19 in the Middle East. In this case-  
182 control study, we investigated the incidence, risk factors and clinical outcomes among hospitalized  
183 patients with pulmonary embolism and COVID-19. The key findings of this study are that smoking  
184 history, a low level of oxygen saturation, and higher D-dimer values were important risk factors that  
185 were associated with a higher risk of developing PE ( $p < 0.05$ ). A higher respiratory rate was associated  
186 with higher odds of death and a decrease in the possibility of survival among hospitalized patients with  
187 PE. We found that around 32% of hospitalized patients with COVID-19 who underwent CTPA were  
188 diagnosed with PE. This finding coincides with previous studies, which reported that about 37.1% of  
189 COVID-19 patients were diagnosed with PE (2). Patients with smoking history values were associated

190 with a higher risk of developing PE. Previous reviews reported a higher risk in current smokers than in  
191 individuals who have never smoked (3). Smoking may promote VTE via different mechanisms such as  
192 a procoagulant state, reduced fibrinolysis, inflammation, and increased blood viscosity (4, 5).

193 In our study, elevated D-dimer was found in all patients with PE and non-PE; an elevated D-dimer  
194 was found in other reports on COVID -19 associated with pneumonia. Researchers attributed this  
195 elevation to excessive consumption of coagulation factors. Some other studies showed that up to 90%  
196 of patients admitted to the hospital for pneumonia had high procoagulant markers, with D-dimer being  
197 one of the most common (6). In our study, there is a significant elevation of D-dimer in the PE group  
198 compared to the control group, indicating that CTPA is necessary for the exclusion of PE if there is  
199 clinical deterioration. This finding coincides with previous studies, which reported that elevated D-  
200 dimer levels correlate with the presence of VTE in COVID-19 patients (7, 8). In our study, patients  
201 without PE had a median D-dimer level of 3.7, similar to 3.3 observed in patients with Covid-19 in the  
202 study by Reich et al. (9).

203 Pharmacological thromboprophylaxis has shown promise in preventing venous thromboembolism  
204 (VTE) for high-risk individuals. The incidence of VTE ranges from 5% to 15% and can be effectively  
205 reduced by one-half to two-thirds with appropriate thromboprophylaxis (10). In critically ill patients,  
206 the incidence of deep vein thrombosis (DVT) ranges from 13% to 31% without thromboprophylaxis  
207 (11). However, this risk can be reduced with pharmacological thromboprophylaxis (12). In our study,  
208 all patients were on thromboprophylaxis per guidelines during hospitalization. This finding heightened  
209 the risk of venous thromboembolism in COVID-19, despite prophylactic anticoagulation.

210 The association between COVID-19 and hypercoagulopathy had been established in the literature.  
211 This hypercoagulable state is found to be correlated with the severity of the illness since both the  
212 incidence and the coagulation abnormalities are more apparent in severe cases. Furthermore, the  
213 presence of coagulation abnormalities such as elevated D-dimer has been linked with both mortality  
214 and the need for mechanical ventilation (13). Despite receiving anticoagulation with at least one  
215 prophylactic dose, the incidence of VTE was approximately 24% (8). Several mechanisms contributed  
216 to the pathogenesis of micro and macro thrombotic complications in COVID-19. These include the  
217 systemic activation of coagulation, and, like other viruses (SARS-COV1 and MERS-COV), SARS-  
218 COV2 promotes endothelial dysfunction, vascular leak, and pulmonary microthrombi (14-16).

219 The major entry receptors of SARS-CoV-2, the angiotensin converting enzyme 2 (ACE2), are located  
220 at the cell surfaces of many organs and regulate renin angiotensin system (RAS). This binding results  
221 in dysregulation of RAS and an increase in the pro-inflammatory cytokines ensuing endothelial  
222 dysfunction and micro thrombosis (17-19). Autopsy studies of COVID-19 cases have shown that  
223 venous thromboembolic events (PE or DVT) are common. Additionally, features of micro thrombosis  
224 and endotheliitis were reported not only in the lungs (20, 21) but also in the heart, intestine and

225 kidneys (22). Additional mechanisms were also described as antiphospholipid antibodies (APSA),  
226 where recent publications have reported the association of APSA with thrombotic complications  
227 observed in COVID-19 patients (23).

228 We did not find significant differences between the PE and non-PE group regarding ICU admission,  
229 connection to mechanical ventilation, survival, or duration of hospital stay. However, the mortality in  
230 patients with PE was around 25.5%; this finding coincides with previous studies, which reported a  
231 mortality rate of about 20% (24). Also, we found no differences between both groups in the other risk  
232 factors for PE, in the duration of hospital admission, and in the duration between admission and the  
233 time of CTPA between both groups; however, this may be due to up-regulation of procoagulant  
234 activity in COVID-19 infection increasing the risk of PE. The coexistence of pneumonia and PE has  
235 been known for years, and data from the international cohort RIETE showed that patients with  
236 respiratory infections had a higher risk of PE procoagulant activity than patients with other types of  
237 infections (25). Patients with coronavirus disease 2019 (COVID-19) pneumonia may be predisposed  
238 to thrombotic complications due to excess inflammatory response, endothelial dysfunction, platelet  
239 activation, and stasis of blood flow (26). In our study, there was no significant difference between  
240 both groups in the duration of hospital admission or the duration between admission and the time of  
241 CTPA, suggesting that there are other mechanisms related to COVID-19 that promote the  
242 coagulopathy, which should be studied in the future.

243 The results of this study demonstrated a high incidence of pulmonary embolism among hospitalized  
244 patients with COVID-19, and this finding should alert health care providers to suspect a diagnosis of  
245 PE in COVID-19 patients, especially when clinical signs are associated with significant elevation of  
246 D-dimer. Further studies are required to determine the duration of thromboprophylaxis in COVID-19  
247 patients.

248 This study has some limitations. First, the number of patients included in the study was small, and the  
249 study population only included patients from a single-centre hospital in Saudi Arabia. Second, due to the  
250 retrospective nature of the study, we did not have data on the CTPA for all suspected PE patients who were  
251 limited by clinical instability or a refusal to do CT with IV contrast. In addition, we were not able to  
252 determine if the PE occurred in hospital or before hospital admission.

## 253 **Conclusions**

254 Our results revealed a high incidence of pulmonary embolism among hospitalized patients with COVID-  
255 19. Preventive measures should be considered for hospitalized patients with smoking history, low level of  
256 oxygen saturation, high D-dimer values, and a high respiratory rate. More studies are required to evaluate  
257 the risk factors and the mechanisms of thrombosis related to COVID-19.

## 258 **AUTHORS CONTRIBUTIONS**

259 Conceptualization, Hassan Alwafi, Omaira Badr and Wael Elrefaey; Data curation, Omaira Badr  
260 and Wael Elrefaey; Formal analysis, Abdallah Y Naser and Hassan Alwafi; Investigation, Omaira  
261 Badr and Hassan Alwafi; Methodology, Abdallah Y Naser and Hassan Alwafi; Project administration,  
262 Omaira Badr and Hassan Alwafi; Resources, Mohammed Shabrawishi, Omaira Badr, Hassan  
263 Alwafi and Wael Elrefaey; Supervision, Omaira Badr and Hassan Alwafi; Validation, Omaira Badr  
264 and Hassan Alwafi; Writing – original draft, Mohammed Shabrawishi, Abdallah Y Naser, Omaira  
265 Badr and Hassan Alwafi; Writing – review & editing, Mohammed Shabrawishi, Abdallah Y Naser,  
266 Omaira Badr, Wael Elrefaey and Hassan Alwafi

## 267 **CONFLICT OF INTEREST**

268 The authors have stated explicitly that there are no conflicts of interest in connection with this article.

## 269 **References**

- 270 1. Shabrawishi M, Al-Gethamy MM, Naser AY, Ghazawi MA, Alsharif GF, Obaid EF, et al. Clinical,  
271 radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PLoS One*.  
272 2020;15(8):e0237130-e.
- 273 2. Kaminetzky M, Moore W, Fansiwala K, Babb JS, Kaminetzky D, Horwitz LI, et al. Pulmonary  
274 Embolism on CTPA in COVID-19 Patients. *Radiol Cardiothorac Imaging*. 2020;2(4):e200308.
- 275 3. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. *Tob*  
276 *Induc Dis*. 2020;18:20-.
- 277 4. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in  
278 cigarette smokers. *Thrombosis and haemostasis*. 1998;79(3):549-53.
- 279 5. Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive  
280 pulmonary disease. *Proceedings of the American Thoracic Society*. 2005;2(1):71-7.
- 281 6. Alonso-Fernández A, Toledo-Pons N, Cosío BG, Millán A, Calvo N, Ramón L, et al. Prevalence  
282 of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A  
283 prospective study. *PLoS One*. 2020;15(8):e0238216-e.
- 284 7. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A  
285 Pooled Analysis. *Thrombosis and haemostasis*. 2020;120(5):876-8.
- 286 8. Chi G, Lee JJ, Jamil A, Gunnam V, Najafi H, Memar Montazerin S, et al. Venous  
287 Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A  
288 Systematic Review and Meta-Analysis. *Journal of clinical medicine*. 2020;9(8).
- 289 9. Rech TH, Girardi AM, Gazzana MB. Incidence of pulmonary embolism in patients with COVID-  
290 19. *Intensive Care Med*. 2020;46(7):1500-1.
- 291 10. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. Venous  
292 thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the  
293 International Medical Prevention Registry on Venous Thromboembolism. *Chest*. 2007;132(3):936-45.
- 294 11. Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical  
295 care. *Journal of critical care*. 2002;17(2):95-104.
- 296 12. Laryea J, Champagne B. Venous thromboembolism prophylaxis. *Clin Colon Rectal Surg*.  
297 2013;26(3):153-9.
- 298 13. Obi AT, Barnes GD, Napolitano LM, Henke PK, Wakefield TW. A narrative review of venous  
299 thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute  
300 respiratory syndrome coronavirus 2 infection. *Journal of vascular surgery Venous and lymphatic*  
301 *disorders*. 2020.

- 302 14. Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, et al. Novel insights on  
303 the pulmonary vascular consequences of COVID-19. *American journal of physiology Lung cellular and*  
304 *molecular physiology*. 2020;319(2):L277-l88.
- 305 15. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-  
306 19, SARS-CoV-1, MERS-CoV and lessons from the past. *Journal of clinical virology : the official*  
307 *publication of the Pan American Society for Clinical Virology*. 2020;127:104362.
- 308 16. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new  
309 potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovascular*  
310 *research*. 2020;116(6):1097-100.
- 311 17. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19  
312 and Its Therapeutic Implications. 2020;127(4):571-87.
- 313 18. Haimei MA. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant  
314 and Thrombotic Complications. *Clinical and Applied Thrombosis/Hemostasis*.  
315 2020;26:1076029620944497.
- 316 19. Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent  
317 implications on the cardiovascular system: From basic science to clinical implications. *J Mol Cell*  
318 *Cardiol*. 2020;144:47-53.
- 319 20. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem  
320 findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *The Lancet*  
321 *Infectious diseases*. 2020;20(10):1135-40.
- 322 21. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and  
323 cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.  
324 *The Lancet Respiratory medicine*. 2020;8(7):681-6.
- 325 22. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.  
326 Endothelial cell infection and endotheliitis in COVID-19. *Lancet (London, England)*.  
327 2020;395(10234):1417-8.
- 328 23. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid  
329 Antibodies in Patients with Covid-19. 2020;382(17):e38.
- 330 24. Xu H, Martin A, Singh A, Narasimhan M, Lau J, Weinberg M, et al. Pulmonary Embolism in  
331 Patients Hospitalized With COVID-19 (From a New York Health System). *Am J Cardiol*. 2020;133:148-  
332 53.
- 333 25. Frasson S, Gussoni G, Di Micco P, Barba R, Bertoletti L, Nuñez MJ, et al. Infection as cause of  
334 immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the  
335 RIETE registry. *Journal of Thrombosis and Thrombolysis*. 2016;41(3):404-12.
- 336 26. Bikkdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and  
337 Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and  
338 Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*.  
339 2020;75(23):2950-73.

#### 340 **TABLES LEGENDS**

341 Table 1: Baseline characteristics for the study sample.

342 Table 2: Vital signs and blood tests upon admission.

343 Table 3: Radiological and ECHO findings

344 Table 4: Risk factors of pulmonary embolism and its survival.

#### 345 **TABLES**

**Table 1: Baseline characteristics for the study sample.**

Demographic variable	Patients with Pulmonary embolism (case) (n= 51)	Patients without Pulmonary embolism (control) (n= 108)	P-Value
<b>Demographics</b>			
Age (years)	56.9 (12.3)	50.9 (15.2)	0.009**
Gender No. (%)			
Male	40 (78.4)	71 (65.7%)	0.139
BMI (kg/m2)	27.7 (5.8)	27.9 (5.8)	0.609
<b>Smoking history</b>			
Smoker	32 (62.7)	29 (26.9)	0.000***
<b>Comorbidities No. (%)</b>			
Diabetes mellitus	24 (47.1)	43 (39.8)	0.388
Hypertension	21 (41.2)	38 (35.2)	0.465
Ischemic heart disease	10 (19.6)	17 (15.7)	0.544
Heart failure	3 (5.9)	6 (5.6)	0.934
Renal failure	0	7 (6.5)	0.060
Malignancy	1 (2.0)	0	0.144
HIV	0	1 (0.9)	0.491
<b>Rheumatologically disease No. (%)</b>			
Rheumatoid arthritis	0	1 (0.9)	0.491
Antiphospholipid syndrome	0	1 (0.9)	0.491
<b>Haematological disease No. (%)</b>			
Sickle cell disease	0	3 (2.8)	0.230
<b>Pulmonary disease (other than pulmonary embolism) No. (%)</b>			

COPD	1 (2.0)	7 (6.5)	0.854
Asthma	1 (2.0)	8 (7.4)	0.719
Tuberculosis	0	2 (1.9)	0.544
IPF	0	1 (0.9)	0.676
Pulmonary hypertension	1 (2.0)	0	0.012*
<b>Sign and symptoms (at presentation to hospital) No. (%)</b>			
Fever	44 (86.3)	80 (74.1)	0.083
Cough	41 (80.4)	85 (78.7)	0.806
Sore throat	20 (39.2)	47 (43.5)	0.608
Dyspnoea	47 (92.2)	98 (90.7)	0.769
Haemoptysis	7 (13.5)	11 (10.2)	0.511
Chest pain	21 (41.2)	26 (24.1)	0.027*
Vomiting	6 (11.8)	28 (25.9)	0.042*
Diarrhea	15 (29.4)	33 (30.6)	0.883
Nausea	21 (41.2)	39 (36.1)	0.539
Loss of smell	4 (7.8)	18 (16.7)	0.133
Loss of taste	4 (7.8)	17 (15.7)	0.170
Headache	22 (43.1)	42 (38.9)	0.610
Bone ache	29 (56.9)	64 (59.3)	0.775
<b>Other No. (%)</b>			
Duration of stay at hospital (median days (IQR))	13.00 (13.00)	15.00 (11.00)	0.983
Duration between admission and spiral (median days)	6.00 (7.00)	5.00 (6.75)	0.953
<b>Outcomes No. (%)</b>			
Survived	38 (74.5)	74 (68.5)	0.440
Died	13 (25.5)	34 (31.5)	0.440
ICU admission (yes)	39 (76.5)	80 (74.1)	0.745

Intubation (yes)	60 (55.6)	32 (62.7)	0.391
Duration of stay at the ICU (median days (IQR))	6.00 (10.00)	7.00 (13.00)	0.524
<b>Medications and management No. (%)</b>			
Mechanical thrombectomy	3 (5.9)	0	0.803
Alteplase	1 (2.0)	0	0.888
<b>Complications of anticoagulant No. (%)</b>			
Minor bleeding	3 (5.9)	0	0.011*

**Table 2: Vital signs and blood tests upon admission.**

Variable	Patients with Pulmonary embolism (case)	Patients without Pulmonary embolism (control)	P-Value
Respiratory rate	30.5 (5.1)	28.3 (6.3)	0.717
Heart rate	113.9 (13.9)	108.9 (20.5)	0.686
Oxygen saturation	83.7 (8.3)	85.8 (6.5)	0.455
Haematocrit	0.38 (0.07)	0.75 (3.6)	0.204
HGB	127.7 (22.9)	122.0 (24.8)	0.913
WBC (median(IQR))	10.27 (7.06)	9.44 (7.00)	0.188
Platelet count	251.00 (135.00)	256.00 (144.0)	0.971
INR	1.09 (0.17)	1.13 (0.28)	0.938
PTT (median(IQR))	35.30 (8.30)	34.30 (7.40)	0.324
PT	13.3 (1.73)	14.50 (4.70)	0.044*
D-dimer (median(IQR))	13.70 (14.38)	3.70 (4.53)	0.000***

**Table 3: Radiological and ECHO findings**

<b>Variable</b>	<b>Patients with Pulmonary embolism (case)</b>	<b>Patients without Pulmonary embolism (control)</b>	<b>P-value</b>
<b>Location of pulmonary embolism</b>			
Segmental branch	23 (45.1)	-	-
Main pulmonary trunk	12 (23.5)	-	-
Lobar branch	10 (19.6)	-	-
Sub segmental	6 (11.8)	-	-
<b>CT parenchymal findings</b>			
Bilateral peripheral ground glass	26 (51.0)	50 (46.3)	0.581
Bilateral peripheral ground glass with	23 (45.1)	50 (46.3)	0.887
Unilateral peripheral ground glass	2 (3.9)	8 (7.4)	0.398
<b>ECHO</b>			
<i>RT ventricular dysfunction</i>	25 (49.0)	22 (20.4)	0.000***
<i>LT ventricular dysfunction</i>	4 (7.8)	8 (7.4)	0.575
<i>Systolic pulmonary hypertension</i>	14 (27.5)	24 (22.2)	0.298

**Table 4: Risk factors of pulmonary embolism and its survival.**

Variable	Risk factors of pulmonary embolism				Factors affecting survival among patients with pulmonary embolism			
	OR (95% CI)	P-value	AOR§ (95% CI)	P-value	OR (95% CI)	P-value	AOR§ (95% CI)	P-value
<b>Demographics and social</b>								
Age (years)	1.03 (1.01 – 1.06)	<b>0.018*</b>	-		0.99 (0.96 – 1.01)	0.230	-	
Gender (female)	0.53 (0.24 – 1.15)	0.107	-		1.19 (0.56 – 2.53)	0.653	-	
Smoking (yes)	4.59 (2.26 – 9.33)	<b>0.000***</b>	3.85 (1.73 – 8.58)	<b>0.001**</b>	1.00 (0.50 – 2.02)	0.991	1.70 (0.46 – 6.27)	0.422
Obesity (BMI> 30 kg/m <sup>2</sup> )	1.40 (0.70 – 2.81)	0.337	-		0.87 (0.43 – 1.78)	0.703	-	
<b>Comorbidities</b>								
Diabetes mellitus (yes)	1.34 (0.69 – 2.63)	0.388	1.02 (0.47 – 2.19)	0.969	0.76 (0.38 – 1.52)	0.440	1.14 (0.35 – 3.71)	0.833
Hypertension (yes)	1.29 (0.65 – 2.55)	0.466	1.21 (0.56 – 2.61)	0.623	0.64 (0.32 – 1.28)	0.202	0.65 (0.20 – 2.09)	0.473
Ischemic heart disease (yes)	1.31 (0.55 – 3.10)	0.545	1.05 (0.40 – 2.77)	0.915	0.81 (0.33 – 1.96)	0.638	0.88 (0.20 – 3.87)	0.870
Heart failure (yes)	1.06 (0.26 – 4.43)	0.934	1.22 (0.25 – 6.09)	0.806	0.50 (0.13 – 1.96)	0.322	0.05 (0.00 – 1.24)	0.068
Renal failure (yes)	-		-		-		-	
Malignancy (yes)	-		-		-		-	
Rheumatologically disease (yes)	-		-		-		-	
Haematological disease (yes)	-		-		-		-	
COPD (yes)	0.79 (0.06 – 10.38)	0.855	-		0.90 (0.12 – 7.03)	0.920	-	
Asthma (yes)	0.63 (0.05 – 8.20)	0.720	-		1.17 (0.15 – 9.01)	0.882	-	

Tuberculosis (yes)	-	-	-	-	-	-	-	-
IPF (yes)	-	-	-	-	-	-	-	-
Pulmonary hypertension (yes)	-	-	-	-	-	-	-	-
<b>Vital signs</b>								
<b>Respiratory rate</b>	1.07 (1.00 – 1.15)	<b>0.043*</b>	1.07 (0.99 – 1.15)	0.076	0.91 (0.84 – 0.98)	<b>0.011*</b>	0.82 (0.71 – 0.94)	<b>0.004**</b>
<b>Heart rate</b>	1.02 (1.00 – 1.04)	0.067	1.02 (1.00 – 1.05)	0.061	0.98 (0.96 – 1.00)	0.113	0.97 (0.94 – 1.01)	0.165
<b>Oxygen saturation</b>	0.98 (0.95 – 1.02)	0.279	0.95 (0.90 – 1.00)	<b>0.039*</b>	1.02 (0.99 – 1.06)	0.272	1.05 (0.97 – 1.15)	0.230
<b>Laboratory</b>								
<b>Haematocrit</b>	0.89 (0.48 – 1.64)	0.705	0.74 (0.01 – 65.73)	0.895	-	-	-	-
<b>HGB</b>	1.01 (0.99 – 1.02)	0.438	1.00 (0.98 – 1.02)	0.790	1.03 (1.01 – 1.04)	<b>0.001**</b>	1.01 (0.98 – 1.03)	0.528
<b>WBC</b>	1.02 (0.97 – 1.07)	0.558	1.02 (0.97 – 1.08)	0.407	0.94 (0.89 – 1.00)	<b>0.035*</b>	0.97 (0.88 – 1.06)	0.468
<b>Platelet count</b>	1.00 (1.00 – 1.00)	0.615	1.00 (1.00 – 1.00)	0.972	1.00 (1.00 – 1.00)	0.580	1.00 (1.00 – 1.00)	0.819
<b>PT</b>	0.91 (0.80 – 1.04)	0.174	0.91 (0.80 – 1.04)	0.180	1.04 (0.94 – 1.16)	0.434	1.00 (0.813 – 1.23)	0.985
<b>PTT</b>	1.00 (0.99 – 1.01)	0.642	1.00 (0.99 – 1.01)	0.491	1.00 (1.00 – 1.01)	0.645	1.03 (0.97 – 1.09)	0.310
<b>INR</b>	1.07 (0.26 – 4.34)	0.925	2.31 (0.30 – 17.65)	0.419	0.12 (0.02 – 0.69)	<b>0.018*</b>	0.05 (0.00 – 1.20)	0.065
<b>D dimer</b>	1.17 (1.10 – 1.24)	<b>0.000***</b>	1.21 (1.13 – 1.30)	<b>0.000***</b>	0.99 (0.96 – 1.01)	0.356	0.99 (0.95 – 1.03)	0.685
<b>Other</b>								
<b>Duration between admission and spiral (days)</b>	0.99 (0.92 – 1.07)	0.862	-	-	0.89 (0.83 – 0.96)	<b>0.003**</b>	-	-
<b>Severity of disease (required ICU admission)</b>	1.14 (0.52 – 2.47)	0.745	1.27 (0.46 – 3.48)	0.646	0.04 (0.01 – 0.31)	<b>0.002**</b>	1.79 (0.09 – 36.12)	0.705

<b>Duration of hospital stay (days)</b>	1.00 (0.96 – 1.04)	0.907	1.01 (0.96 – 1.07)	0.695	0.96 (0.93 – 1.00)	<b>0.042*</b>	1.10 (1.00 – 1.21)	0.053
<b>Duration of stay in the ICU (days)</b>	0.98 (0.94 – 1.02)	0.395	-		0.86 (0.82 – 0.91)	<b>0.000***</b>	-	
<b>Intubation (yes)</b>	0.74 (0.38 – 1.47)	0.392	-		0.01 (0.00 – 0.05)	<b>0.000***</b>	-	

§ Adjusted for the following variables: age, gender, BMI, renal failure, malignancy, haematological diseases, duration between admission and spiral, duration in the ICU, and intubation

